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Abstract
As the incidence of Malignant Melanoma (MM) reflects an interaction between skin colour and UV exposure, variations in
genes implicated in pigmentation and tanning response to UV may be associated with susceptibility to MM. In this study,
363 SNPs in 65 gene regions belonging to the pigmentation pathway have been successfully genotyped using a SNP array.
Five hundred and ninety MM cases and 507 controls were analyzed in a discovery phase I. Ten candidate SNPs based on a
p-value threshold of 0.01 were identified. Two of them, rs35414 (SLC45A2) and rs2069398 (SILV/CKD2), were statistically
significant after conservative Bonferroni correction. The best six SNPs were further tested in an independent Spanish series
(624 MM cases and 789 controls). A novel SNP located on the SLC45A2 gene (rs35414) was found to be significantly
associated with melanoma in both phase I and phase II (P,0.0001). None of the other five SNPs were replicated in this
second phase of the study. However, three SNPs in TYR, SILV/CDK2 and ADAMTS20 genes (rs17793678, rs2069398 and
rs1510521 respectively) had an overall p-value,0.05 when considering the whole DNA collection (1214 MM cases and 1296
controls). Both the SLC45A2 and the SILV/CDK2 variants behave as protective alleles, while the TYR and ADAMTS20 variants
seem to function as risk alleles. Cumulative effects were detected when these four variants were considered together.
Furthermore, individuals carrying two or more mutations in MC1R, a well-known low penetrance melanoma-predisposing
gene, had a decreased MM risk if concurrently bearing the SLC45A2 protective variant. To our knowledge, this is the largest
study on Spanish sporadic MM cases to date.
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Malignant melanoma (MM) is a cancer of melanocytes
(pigment-producing cells) located predominantly along the basal
layer of the epidermis, but also found in mucous membranes. The
most relevant epidemiologic characteristic of MM is its increasing
incidence among Caucasian populations [1]. The aetiology of MM
remains unclear but it is known that both genetic and
environmental factors influence the development of sporadic
disease [2].
If putative genetic pathways involved in MM susceptibility are
considered, the human pigmentation pathway seems to have a
main role in the pathogenesis of the disease. MM predisposition is
highest in fair skin, high mole count, blond or red-haired
individuals who never tan and always burn (Fitzpatrick’s
phototypes I and II) [2]. Since the incidence of MM reflects an
interaction between skin colour and UV exposure, variations in
genes implicated in pigmentation and tanning response to UV
may be associated with susceptibility to MM and may be useful
predictors of MM risk in the general population [3–6].
In recent years, considerable effort has been devoted to
understanding the role of low penetrance genes in the pathogenesis
of cancer. Linkage analysis infamilies affected with cancerhas ledto
the identification of highly penetrant MM cancer genes: CDKN2A
(MIM#60160) and CDK4 (MIM#609048) [2]. However, indi-
vidual high-risk alleles are generally uncommon, hence many
other low penetrance genes have been considered to be involved
in the pathogenesis of MM, each contributing a small effect to the
total genetic component [7]. To date, only one gene, the
melanocortin 1 receptor gene (MC1R; MIM#155555), is known
to unequivocally account for a substantial variation in the incidence
of sporadic MM [8–13]. Moreover, several other genes, such as
OCA2 (MIM#611409), ASIP (MIM#600201) and SLC45A2
(MIM#606202) have also emerged as being potentially important
in MM susceptibility [14–18]. Recently, with the emergence of
‘‘large-scale genome-wide association studies’’ (GWAS), it has
become feasible to perform a systematic search for other low to
moderate risk-conferring alleles that could contribute to sporadic
MM. Several GWAS have identified genomic regions associated
with MM or with pigmentation characteristics such as hair and eye
colour, skin sensitivity to sun and freckling. Genetic regions near
the ASIP (MIM#600201), E2F1 (MIM#189971), SLC24A4
(MIM#210750, KITLG (MIM#611664), TYR (MIM#606933),
OCA2/HERC2 (MIM#605837), MC1R (MIM#155555) or
SLC45A2 (MIM#606202) genes [14,19–21] seem to be involved
in pigmentation and/or MM susceptibility.
Considering the involvement of pigmentation in MM predis-
position, we investigated the role of 384 polymorphisms in 65
pigmentation gene regions in MM susceptibility using two large
independent series of Spanish samples (1214 MM cases and 1296
controls in total). To our knowledge, this is the largest study on
Spanish sporadic MM cases to date.
Results
From the initial list of 384 variants, 21 SNPs (5.4%) were
discarded due to failed genotyping (no PCR amplification,
insufficient intensity for cluster separation or poor cluster
definition). Overall, 363 SNPs were studied, representing all
initially selected genes. Evidence of departure from HWE among
controls was observed for ten SNPs, although none of them
remained statistically significant after a conservative Bonferroni
correction for multiple testing. The number of SNPs successfully
genotyped in each gene in discovery phase I is included in Table
S1. Their genomic positions are summarized as follows: 256
intronic (66.7%), 47 59 UTR upstream (12.5%), 64 39 UTR
downstream (16.7%) and 16 coding (4.2%).
Comparison of allele frequencies
Estimated allele frequencies for all 363 SNPs based on the
Spanish sample are provided in Table S1. We compared our
Spanish frequencies to those of HapMap CEU subjects, using the
HapMap minor allele as the reference (Figure 1). Frequencies were
very similar, with a high positive correlation (R
2) of 0.85. For 20
SNPs (5.5%), the minor allele reported in HapMap was found to
be the most frequent allele in the Spanish sample (values above the
dotted horizontal line in Figure 1). For 143 of the 363 SNPs
considered (39%), one-sample t-test gave evidence that the
corresponding Spanish minor allele frequency (MAF) differed
from that published in HapMap (p,0.05) (shown in dark grey in
Figure 1). However, when the Bonferroni correction was applied
Figure 1. Comparison of minor allele frequencies, Spanish versus HapMap European data. Black dots represent values that significantly
differ from HapMap European data, when sample size was considered (not corrected by Bonferroni method).
doi:10.1371/journal.pone.0019271.g001
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from HapMap data.
Associations with MM risk
Representation of 2log10 p-values for the comparison of MAFs
between the 590 Spanish MM cases and the 507 controls are
detailed in Figure 2. Considering a p-value threshold of 0.05, 30
SNPs located in 18 genes on eleven individual chromosomes were
associated with MM in the Spanish population. Detailed
information on rs number, genes, chromosome location, MAFs,
OR, 95% CI and p-values for comparisons between cases and
control subjects are represented in Table S2. However, if a more
restrictive p-value threshold of 0.01 is established, only ten SNPs,
located in six genes (one in each of ADAMTS20, TYR and SILV-
CDK2; two in each of KIT and MYO7A; and three in SLC45A2)o n
six individual chromosomes constituted the top ten MM associated
SNPs in our Spanish population. Among them, two SNPs (rs35414
and rs2069398), located in two different genes (SLC45A2
and SILV-CDK2 respectively), are statistically significant after
applying the Bonferroni correction for multiple comparisons
(p-value=0.0001). Results, including SNP chromosome and gene
region, allele frequencies of the top ten MM-associated SNPs,
p-values from comparisons between cases and controls and p-values
for Bonferroni correction are summarized in Table 1.
From these ten associated SNPs, the one with the best p-value in
each gene (six SNPs) was chosen to be studied in validation phase
II, consisting on an independent Spanish set of 624 MM cases and
789 controls. The concordance rate between duplicate samples in
the quality control analysis was 100%. None of the SNPs
presented evidence of departure from HWE. One SNP, rs35414
in SLC45A2 gene, had an unadjusted p-value=0.002 in phase II
and an overall p-value,0.0001 with an overall OR=0.75 (95% CI
0.67–0.84) (Figure 3). None of the other five SNPs tested in phase
II reached statistical significance at this stage. However, three of
them, located in TYR, SILV-CDK2 and ADAMTS20 had an overall
p-value,0.05 when phase I and II were considered together
Figure 2. Pigmentation SNP array association results. The –log10 of the allelic p-values from 363 polymorphic SNPs comparing 590 melanoma
cases and 507 controls of Spanish origin are represented. The chromosomal SNP distribution is shown. Two values remained statistically significant
after Bonferroni correction ‘‘pBonf=0.04’’.
doi:10.1371/journal.pone.0019271.g002
Table 1. Top ten SNPs associated with Malignant Melanoma p,0.01.
Gene Ma/M MAF MAF
Symbol Chr SNP Allele Cases Controls OR (95% CI) p-value p-B
KIT 4 rs759083 C/G 0.40 0.34 1.26 (1.06–1.50) 0.009 1
rs13135792 T/C 0.38 0.33 1.27 (1.07–1.52) 0.0071 1
SLC45A2 5 rs35405 C/T 0.48 0.42 1.26 (1.06–1.49) 0.0084 1
rs35414 C/T 0.37 0.45 0.71 (0.60–0.84) 0.0001 0.04
rs35415 C/A 0.39 0.47 0.73 (0.62–0.87) 0.0004 0.14
MYO7A 11 rs948970 C/G 0.44 0.49 0.80 (0.68–0.94) 0.0098 1
rs3758708 G/A 0.13 0.08 1.63 (1.20–2.22) 0.0016 0.58
TYR 11 rs17793678 C/T 0.28 0.23 1.32 (1.09–1.60) 0.0049 1
ADAMTS20 12 rs1510521 T/C 0.37 0.31 1.30 (1.09–1.55) 0.0039 1
SILV-CDK2 12 rs2069398 G/A 0.06 0.10 0.52 (0.38–0.72) 0.0001 0.04
Ma, Major; Mi, Minor; MAF, minor allele frequency; OR, odds ratio per minor allele; CI, confidence interval; B, Bonferroni.
Bold indicates statistically significant results.
doi:10.1371/journal.pone.0019271.t001
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rs17793678 in an intronic region of the TYR gene with an overall
OR=1.22 (95% CI 1.07–1.34, p-value=0.003); rs2069398 located
in exon 1 of the CDK2 gene and a putative promoter region of the
SILV gene, with an overall OR=0.73 (95% CI 0.58–0.90,
p-value=0.004); and rs1510521 in an ADAMTS20 intron with an
overall OR=1.13 (95% CI 1.001–1.27, p-value=0.048). A fourth
SNP, rs3758708 in the MYO7A gene, was marginally associated
with MM (OR=1.18, 95% CI 0.98–1.41, p-value=0.09).
We observed some degree of epistatic protective interaction
between rs35414 (SLC45A2 gene) and rs2069398 (SILV-CDK2
gene region) when considering rare allele carriers at both loci.
Results including joint genotypes (rs35414 and rs2069398),
status of individuals (controls or cases), total number of samples,
ORs (95% CI) and p-values are shown in Table 2a. We observed
a significant decrease in OR when two or three of the rare
alleles were present at both loci, rs35414 C/T and rs2069390
A/-, OR 0.54 (95% CI 0.39–0.75) p-value=0.0003, and when
three or four rare alleles, rs35414 T/T and rs2069390 A/-, were
present we obtained and OR=0.31 (95% CI 0.18–0.55) with
p-value=0.0001.
Furthermore, some degree of epistatic risk interaction was also
seen between rs17793678 (TYR) and rs1510521 (ADAMTS20)
when considering rare alleles at both loci. Results including joint
genotypes (rs17793678 and rs1510521), status of individuals
(controls or cases), total number of samples and ORs (95% CI)
and p-values are shown in Table 2b. We observed a risk effect
when two or three rare alleles were present at both loci,
rs17793678 C/T and rs1510521 G/-, OR=1.41 (95% CI
1.12–1.78) p-value=0.004, and when three or four rare alleles,
rs17793678 T/T and rs1510521 G/- were present, we obtained
an OR=1.54 (95% CI 0.96–2.48) with a trend toward
significance (p-value=0.088).
The role of SLC45A2 in melanoma predisposition was further
analyzed in relation to MC1R, the main low penetrance gene
associated to melanoma. Since both genes have been studied by
our group, the interaction effects between both loci (see Table 2c)
were investigated [22]. A great reduction of risk was detected
when the rare protective alleles at SLC45A2 were combined with
two or more MC1R variants (OR=2.20; 95% CI 1.14–4.23;
p-value=0.02), in comparison to individuals carrying only MC1R
variants (OR=4.64; 95% CI 1.85–11.58; p-value=0.001). Indi-
viduals having only one MC1R mutation also show a reduction in
MM risk, although this decline does not seem to reach significant
values (Table 2c). These results confirm the protective role of the
rs35414 variant in SLC45A2 regarding MM risk. Additional
comparisons with HERC2/OCA2 rs12913838 did not add more
information.
Associations of top ten MM-associated SNPs with
phenotypic characteristics
Evidence of association with phenotypic characteristics for the
top ten MM-associated SNPs was also assessed. Both KIT SNPs
rs759083 and rs13135792 appeared to be associated with both
light hair colour (p=0.0021 and p=0.0072) and childhood
sunburns (p=0.0112 and p=0.0167). SLC45A2 SNPs rs35414
and rs35415 were associated with dark skin colour (p=0.028 and
p=0.0485) and only rs35414 with dark hair colour (p=0.0183).
Two different SNPs in MYO7A were associated with dark hair
colour (rs948970) (p=0.04), and childhood sunburn (rs3758708)
(p=0.0474). One SNP in the TYR gene (rs17793678) was
associated with light eye colour (p=0.0239). Likewise, the
ADAMTS20 gene was associated with light eye colour
(p=0.0339), blond or red hair colour (p=0.0353) and with
number of naevi ,50 (rs1510521; p=0.0338). Finally, SILV-CDK2
SNP rs2069398 was associated with absence of childhood
sunburns (p=0.0353). Table S3 summarizes results for eye, skin
and hair colour, presence of childhood sunburns, number of naevi
and the presence of solar lentigines. Results in bold represent those
with associated p-values,0.05.
Haplotype structure at the SLC45A2 locus with reported
associations with MM
The SLC45A2 gene haplotype structure (obtained using
HapMap data) is shown in Figure S1. This locus, located in
chromosome 5, is represented by two main haploblocks, one
located at the 39 end of the gene (2 kb), and another one
comprising the 59 end of the gene (13 kb), which includes part of
intron 1 and the closest putative promoter. SNPs located between
these two LD blocks are not defined in any additional block
structure, probably due to their low minor allele frequencies.
Additional analyses using HapMap data were performed. These
analyses included three SNPs previously associated with MM at
the SLC45A2 locus: p.F374L (rs16891982), rs35391 and rs28777
[15,23,24], together with the rs35414 variant associated with MM
in this study. The four SNPs under consideration are located in
chromosome 5 in the following order: rs16891982 (p.F374L);
rs35391; rs28777 and rs35414 (HapMap). The analysis revealed
five different haplotypes (see Table S4), of which two are by far the
most common: GCAC (66.7%) and GCAT (29.4%). This last
haplotype carries the protective T allele at rs35414. Haplotype
CCCT (1%) carries the rare C allele at the p.F374L amino acid
change as well as the rare C allele at rs28777. Minor C allele at
rs28777 is only present in a low frequency haplotype (GCCC 2%).
In the HapMap database, we did not observe any haplotypes
carrying the rare T allele at rs35391 due to its low frequency in
Caucasians.
Discussion
In this study, 363 tag SNPs in 65 pigmentation-related gene
regions were successfully genotyped in 590 MM cases and 507
controls in discovery phase I. In addition, 624 MM cases and 789
controls were genotyped for the top six MM-associated SNPs in
validation phase II. Thus, a total of 1214 MM cases and 1296
controls have been evaluated in this study. Among 363 SNPs in 65
pigmentation gene regions, allele frequencies were highly
correlated between the HapMap (CEU) and the Spanish samples
(R
2=0.85). Despite of 143 SNPs with minor allele frequencies
different from those published in HapMap, none remained
significant after multiple testing (Bonferroni correction). Although
the published HapMap MAFs should probably not be taken as
definitive (at least for a Southern European population), overall,
the HapMap CEU sample is representative of the Spanish
population. Therefore, the HapMap data can be used in assessing
the appropriateness of SNPs for inclusion in association studies
Figure 3. Forest plot showing the six most associated polymorphisms with melanoma risk predisposition. Dots represent odds ratios in
the treated sub-groups versus those in control groups. Diamond shapes represent pooled results for each phase, discovery (phase I) and validation
(phase II). Squares represent the overall odds ratios. The size of the square is proportional to the number of individuals, and error bars represent 95%
confidence intervals.
doi:10.1371/journal.pone.0019271.g003
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implications.
From discovery phase I, p-values below 0.05 were obtained for
30 SNPs and, of these, ten final candidate SNPs, based on an
arbitrary p-value threshold of 0.01, were identified. We were
encouraged to follow a validation phase due to two SNPs (rs35414
and rs2069398) remaining statistically significant after Bonferroni
correction. After testing six of these ten SNPs in an independent
Spanish series with 624 MM cases and 789 controls, one SNP
(rs35414) on an intronic region of the SLC45A2 gene significantly
associated with melanoma was confirmed (p,0.0001). Three
additional SNPs in TYR, SILV/CDK2 and ADAMTS20
(rs17793678, rs2069398 and rs1510521 respectively) had an
overall p-value,0.05 when considering the whole data set
(1214 MM cases and 1296 controls). However, in validation
phase II, data for these three SNPs did not reach statistical
significant results per se.
Recent GWAS have unveiled association between SNPs or
genetic variants in MC1R, TPCN2, ASIP, KITLG, SLC24A5,
TYR, IRF4, OCA2/HERC2, SLC24A4, SLC45A2, TYRP1, and
pigmentation as well as melanoma. These findings emphasize
the contribution of pigmentation to melanoma predisposition
and tumourigenesis through gene-environment interactions
[19–21,25].
The top predisposing MM-associated gene in our study has
functions related to melanosomal formation, maturation and
transportation. The SLC45A2 gene (MIM#606202) encodes a
protein that acts, presumably, as a membrane-associated trans-
porter [26–28]. SLC45A2 exhibits structural homology to plant
sucrose-proton symporters and probably directs the traffic of
melanosomal proteins and other substances to the melanosomes
[29]. SLC45A2 mutations cause pigmentation variation in several
organisms [27,30–33]. In humans, pathogenic mutations in
SLC45A2 lead to type IV oculocutaneous albinism (OCA4) [26].
SLC45A2 mutations disrupt tyrosinase processing and trafficking at
the post-Golgi level [34,35]. Other variants located on the
promoter and in exonic sequences on the SLC45A2 gene have
been shown to be significantly associated with dark hair, skin, and
eye pigmentation in Caucasian populations [15,23,28,36]. Previ-
ous results from our group and others show that the coding variant
c.1122C.G (p.F374L, rs16891982) has been associated with
protection against melanoma susceptibility in Southern European
populations [15,23]. In addition, a recent study by Duffy and cols.
([24]) has detected protective effects of SLC45A2 through three
Table 2. Interactions between protective (a) and risk (b) variants and their effect on MM susceptibility.
a
Joint genotype Spanish population
rs35414 (SLC45A2) rs2069398 (SILV) Cases Controls N OR (95%CI) p-value
C/C G/G 431 340 771 1 REF
A/- 54 57 111 0.75 (0.50–1.11) 0.15
C/T G/G 485 538 1023 0.71 (0.59–0.86) 0.0004
A/- 70 103 173 0.54 (0.39–0.75) 0.0003
T/T G/G 149 199 348 0.59 (0.46–0.76) 0.0001
A/- 17 43 60 0.31 (0.18–0.55) 0.0001
b
Joint genotype Spanish population
rs17793678 (TYR) rs1510521 (ADAMTS20) Cases Controls N OR (95%CI) p-value
C/C A/A 297 371 668 1 REF
G/- 361 382 743 1.18 (0.96–1.46) 0.122
C/T A/A 203 224 427 1.13 (0.89–1.44) 0.321
G/- 260 230 490 1.41 (1.12–1.78) 0.004
T/T A/A 40 25 65 1.99 (1.19–3.35) 0.009
G/- 42 34 76 1.54 (0.96–2.48) 0.088
c
Joint genotype Spanish population
MC1R rs35414 (SLC45A2) Cases Controls N OR (95%CI) p-value
0 C/C 63 39 102 1 REF
T/- 95 133 228 0.44 (0.27–0.71) 0.001
1 C/C 71 39 110 1.13 (0.65–1.97) 0.78
T/- 119 114 233 0.65 (0.40–1.04) 0.08
2/+ C/C 45 6 51 4.64 (1.85–11.58) 0.001
T/- 64 18 82 2.20 (1.14–4.23) 0.02
OR, odds ratio per minor allele; CI. Confidence interval; REF. Reference value.
Bold indicates statistically significant results.
doi:10.1371/journal.pone.0019271.t002
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study concludes that the two noncoding SNPs, rs35391 and
rs28777, are in LD with each other and are not significant
melanoma risk predictors in a multivariate logistic regression
models after adjusting for rs16891982 (p.F374L). They confirm
that rs16891982 is the SNP most strongly associated with
melanoma risk in their population. These three SNPs are placed
in the middle region of the SLC45A2 gene, a segment of the gene
that, according to HapMap data, does not belong to any block
structure (probably due to their low minor allele frequencies in the
Caucasian population where they were genotyped) (Figure S1).
The results obtained in this study support the protective role of
SLC45A2and propose two novel intronic SNPs associated with MM
predisposition. Both of these SNPs, rs35414 and rs35415, are
located inside intron 1 of the SLC45A2 gene. rs35415 (p-value 0.0004
in phase I) was selected as the tag of the LD block located at the 59
end of the gene, while rs35414, studied in phase I and validated in
phase II (global p-value=0.0001), is located in a region without
apparent LD block structure (Figure S1). However, both SNPs
(rs35414 and rs35415) are in strong linkage disequilibrium with
each other (R
2=0.95) (Figure S1). Both constitute the second most
common haplotype of the gene (43%), also conferring protection
against melanoma (p-value=0.0001). Thus, the association of this 59
end region to MM predisposition suggests a putative involvement of
unknown functional variants, in LD with these SNPs, involving
regulatory elements in the promoter region of the SLC45A2 gene.
Furthermore, the protective role of the rs35414 variant in
SLC45A2 is reinforced due to its capability to modulate the MM
risk conferred by the MC1R locus.
Although no additional SNPs were replicatedin the second phase
of the study, three of them had statistical significance when the
entire data collection was taken as a whole. Therefore, we consider
them as quite relevant for further validations in other populations.
SILV (MIM#155550) melanosomal matrix protein represents a
melanoma specific antigen recognized by tumour infiltrating
cytotoxic T lymphocytes [37]. It is also known as PMEL17, GP100
or ME20 [38] and it is crucial for proper formation and
maturation of melanosomes. In stage II melanosomes, processed
SILV protein aggregates to form fibrils, to which presumably the
eumelanin pigment is attached [39]. It was found to be
orthologous to the mouse silver locus. In this study, SNP
rs2069398 was selected in order to represent the 59end of the
SILV gene. Interestingly, the SILV locus is flanked quite closely on
each side by CDK2 and DGKA at distances of 829 and 193bp,
respectively, placed head to head with CDK2 in such a way as to
allow sharing or overlapping promoter elements [40]. rs2069398 is
located in exon1 of the CDK2 gene, resulting in the synonymous
polymorphism c.84G.A, p.Glu28Glu. The significance of this
gene arrangement and the putative functionality of this SNP are
yet to be tested.
The human tyrosinase gene (TYR, MIM#606933) is another
melanosomal membrane-bound enzyme that catalyzes the first
two rate-limiting steps in the melanin biosynthesis pathway [41].
Mutations in the TYR gene cause the most severe form of
oculocutaneous albinism OCA1 (TYR, MIM 606933, OCA1,
MIM 203100) [42]. MM associated SNP rs17793678 is located in
intron 1 and was selected as the tag for one of the five most
frequent haplotypes formed at the promoter LD block in this gene
(19 kb). Interestingly, TYR has previously been associated with
melanoma in GWAS studies [18] performed in Caucasian
populations other than our South European sample.
Finally, the ADAMTS20 protein (A disintegrin-like and
metalloprotease domain with thrombospondin type-1 motifs,
MIM#611681) is a member of a family of secreted metallopro-
teases that can process a variety of extracellular matrix
components and secreted molecules. Adamts20 mutations in belted
(bt) mice cause white spotting of the dorsal and ventral torso,
indicative of defective neural crest-derived melanoblast develop-
ment and thus implicating metalloproteases in skin pigmentation
[43]. A role for Adamts20 in melanoblast survival has been
described [44]. In our study, SNP rs1510521 was selected as the
tag of the most frequent haplotype of the large LD block at the 39
end of the gene (107 kb), containing the majority of the gene
region with the exception of the first three exons. Additional
studies are needed in order to clarify the role of ADAMTS20 in
MM susceptibility.
Since SLC45A2 and TYR genes have already been associated
with MM [15,18,23,24], it seemed biologically plausible that
genetic interactions would be detected between protective
SLC45A2 and SILV/CDK2 variants and, similarly, between risks
variants within TYR and ADAMTS20. Indeed, both effects were
observed when summing up rare alleles as it has been described for
other interactions among pigmentation genes [24,45]. On one
hand, a great reduction of risk was detected when rare alleles at
SLC45A2 and SILV/CDK2 genes were combined (OR=0.31;
p=0.0001). On the other hand, an increased risk, although
marginally significant, appeared with the combination of rare
alleles at TYR and ADAMTS20 (OR=1.54; p=0.088) (See
Table 2).
We were not able to clearly detect any other gene association
with MM in our study. However, several candidate genes that may
be of interest to other pigmentation and/or MM studies are
present in the list of the 30 SNPs with p,0.05. Unfortunately,
some genes already known to be associated with pigmentation
were not selected due to reasons such as large gene size, lack of
suitable tag SNPs within the gene, genes lying in high copy
number regions, etc. We acknowledge the fact that our sample set
comes from different hospitals distributed throughout different
Spanish provinces. However, a recent work by Laayouni and cols.
using a 300K-SNP Illumina array demonstrates lack of genetic
heterogeneity within different Spanish regions including the
Basque country [46].
In summary, we conducted a two-stage MM susceptibility case-
control study (candidate SNP selection and replication). First, we
screened 363 tag-SNPs in 65 pigmentation-related gene regions in
a large Spanish case-control series. Then we validated observed
associations in an independent Spanish series, making this the
largest sporadic MM susceptibility study in the Spanish population
up to now. One SNP (rs35414) on an intronic region of the
SLC45A2 gene was associated with MM risk after adjustment for
multiple testing in phase I and II, indicating that common
variation in SLC45A2 is associated with protection from the
disease. Nevertheless, further studies are welcomed to add weight
to our conclusions. We also show that carrying this protective
variant decreases the risk of developing MM in bearers of two or
more mutations in MC1R, a well-known low penetrance MM
predisposing gene. Moreover, three additional variants in TYR,
SILV/CDK2 and ADAMTS20 (rs17793678, rs2069398 and
rs1510521 respectively) had an overall p-value,0.05, emphasizing
the importance of pigmentation genes on MM risk.
Materials and Methods
Study Subjects and Data Collection
Discovery Phase I. A total number of 590 sporadic MM
cases were recruited from September 2004 to November 2008 at
the Departments of Dermatology of five Spanish hospitals:
Gregorio Maran ˜on General University Hospital (Madrid), La
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Hospital (Madrid), Castellon Province Hospital (Castellon), Cruces
University Public Hospital (Barakaldo) and Basurto University
Public Hospital (Bilbao). Similarly, 507 cancer-free controls were
recruited from the Madrid College of Lawyers, Gregorio Maran ˜on
Hospital, Castellon Province Hospital and the University of the
Basque Country.
A standardized questionnaire was used to collect information on
pigmentation characteristics (eye colour, hair colour, skin colour,
number of naevi and presence of solar lentigines), the presence of
childhood sunburns, Fitzpatrick’s skin type classification (see Table
S5), and personal and family history of cancer.
Validation Phase II. A second phase of the study, consisting
of an independent validation series, was composed of 624 non-
related sporadic MM cases obtained from the Departments of
Dermatology of Instituto Valenciano de Oncologia (Valencia) and
Hospital Dr. Negrin from Las Palmas (Gran Canaria), Spain. A
total of 789 cancer-free controls from the same two institutions
were recruited. All subjects came from the geographical regions
covered by the hospitals involved in the study. A recent work by
Laayouni and cols. demonstrates lack of genetic heterogeneity
within different Spanish regions, including the Basque country, by
genome-wide single nucleotide polymorphism (SNP) array [46].
Sample distribution is listed in Table 3 (a+b).
Genomic DNA from cases and controls was isolated from
peripheral blood lymphocytes and diluted to a final solution of
50 ng/ml. For the control subjects, this was done using the MagNA
Pure LC Instrument according to the manufacturer’s protocol
(Roche Applied Science, Mannheim, Germany) or the DNAzol
procedure (Invitrogen, Eugene, OR, USA). The traditional saline
method was used for MM cases. Quality control was performed
for all samples before processing them on the Illumina arrays.
DNA concentration was quantified in samples prior to genotyping
by using Quant-iT PicoGreen dsDNA Reagent (Invitrogen,
Eugene, OR, USA).
All subjects gave written informed consent and the study was
approved by the Ethics Committee of Gregorio Maran ˜on Hospital
and University Clinic Hospital.
Gene and SNP Selection
Previous literature, information of public databases and
information based on expression arrays [47] were used to perform
gene selection in our candidate gene approach study. Genes were
classified using Gene Ontology categories [48] with the help of the
DAVID programmes [49]. Finally, 65 gene regions were included
in the study (final list of genes available in Table S6). They covered
a broad range of biological processes. Nevertheless, the most
overrepresented categories were pigmentation GO:0043473 (27
genes, p-value=5.77610
232); pigmentation during development
GO:0048066 (19 genes with p-value=2.13610
221) and cellular
pigmentation GO:0033059 (11 genes, p-value=2.9610
218). An-
other overrepresented category was membrane-bounded vesicle
GO: 0031988 (12 genes, p-value=1.39610
211), that includes genes
coding for proteins located in the melanosome membrane
(specialized lysosome implicated in melanin transport). Thus, their
functions are related to pigmentation.
Our group had already analyzed exonic and putative functional
SNPs in 15 genes associated with pigmentation syndromes or
associated to defects in mice pigmentation [50]. However, in the
current study, selected genes were analyzed using tag-SNPs
ranging from the hypothetical promoter area (approximately
10 kb upstream) until approximately 5 kb downstream of the
gene. SNP codes, locations, and frequencies were obtained from
the NCBI (www.ncbi.nlm.nih.gov/SNP), HapMap (www.hapmap.
Table 3. Sample distribution along discovery (phase I) and validation (phase II) sets*.
Discovery Group (Phase I)
Sub-Group Institution Origin Cases (N=590) Controls (N=507)
n( % ) n( % )
CM Gregorio Maran ˜on Hospital 155 (26.27) 27 (5.33)
Ramon y Cajal Hospital 120 (20.34) 0 (0.00)
La Paz Hospital 72 (12.2) 0 (0.00)
Madrid College of Lawyers 0 (0.00) 218 (43.00)
Sub-Total 347 (58.81) 245 (48.32)
CS Castellon Province Hospital 110 (18.64) 104 (20.51)
Sub-total 110 (18.64) 104 (20.51)
PV Basurto Hospital 110 (18.64) 0 (0.00)
Cruces Hospital 23 (3.90) 0 (0.00)
University of the Basque Country 0 (0.00) 158 (31.16)
Sub-Total 133 (22.54) 158 (31.16)
Validation Group (Phase II)
Sub-Group Institution Origin Cases (N=624) Controls (N=507)
n( % ) n( % )
Va Instituto Valenciano Oncologia 412 (66.02) 558 (70.72)
LP Dr. Negrin Hospital 212 (33.97) 231 (29.27)
CM (Comunidad Madrid); CS (Castellon); PV (Pais Vasco); Va (Valencia); LP (Las Palmas de Gran Canaria).
*Total Discovery and validation sets were formed by 1214 Melanomas and 1296 control samples.
doi:10.1371/journal.pone.0019271.t003
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infer Linkage Disequilibrium (LD) blocks according to the
HapMap project. To ensure a high genotyping success rate, a
minor allele frequency threshold of 0.05 in the HapMap CEU
population and an ‘Illumina score’ of not less than 0.6 (as
recommended by the manufacturer) were established in the SNP
selection process.
SNP Genotyping
SNPs were genotyped using the GoldenGate Genotyping Assay
system according to the manufacturer’s protocol (Illumina, San
Diego, CA, USA). Genotyping was carried out using 350
nanograms of DNA per reaction. Genotyping specificity was
assessed by including three DNA duplicates (two intra-assays and
one inter-assay) and a negative control in each 96-well plate
genotyped, yielding 100% consistent replication results. In
addition, cases and control samples were always included in the
same run. Genotypes were called using the proprietary software
supplied by Illumina (BeadStudio, version 3.1.3.).
Validation set genotyping was carried out using the TaqMan
platform according to the manufacturer’s protocol (Applied
Biosystems, Foster City, CA, USA). For this validation, the six
selected SNPs were analyzed using Taqman
R SNP Genotyping
Assays TYR (NM_000372.4) rs17793678, C_34306017_10; KIT
(NM_000222.2) rs13135792, C_3288591_10; SLC45A2 (NM_
016180.3) rs35414, C_2390581_10; SILV/CDK2 (NM_006928.3)
rs2069398, C_15793372_10; ADAMTS20 (NM_025003.3) rs1510521,
C_7519176_10 and MYO7A (NM_000260.3) rs3758708, C_
27475322_10. Fifteen nanograms of DNA were used for the
genotyping reactions. The genotype of each sample was automatically
determined by measuring allele-specific final fluorescence in an ABI
Prism 7900HT Detection System, using SDS 2.3 software for allele
discrimination (Applied Biosystems, Foster City, CA, USA). As a
quality control measure, at least two sample duplicates and a non-
template sample per 96-well plate were included. Genotypes were
scored bytwo different personnel in the laboratory. A concordance rate
of 100% was obtained for all the SNPs tested.
Haplotype analysis
Haplotype information was obtained from the HapMap
database (www.hapmap.org), using available data from the
SLC45A2 gene (Chromosome 5; 33,975,000–34,025,000; version
28).
Statistical Analysis
Quality control processes and allelic and genotypic association
tests were performed using the SNPator package in discovery
phase I (www.snpator.com). Analyses performed in the validation
set were conducted using SPSS v17.
For all polymorphisms studied, Fisher’s exact test was used both
to test for deviations from Hardy-Weinberg equilibrium (HWE)
among controls and to compare allele counts between cases and
controls. Correction for multiple testing was carried out using the
Bonferroni method. Genotype-related odds ratios, their corre-
sponding 95% confidence intervals and associated p-values were
estimated via unconditional logistic regression. Multivariate
logistic regression was also applied, including age (categorical:
,30, 30–39, 40–49, 50–59, 60–69, 70–79, $80), sex (male,
female), hair colour (brown/black, blond/red), skin colour (fair,
brown), lentigines (yes, no) and childhood sunburn (yes, no) as
covariates. Associations between the genotyped pigmentation
genes and various pigmentation characteristics and sun sensibility
were assessed via logistic regression. This was done for cases and
controls combined, with eye colour (blue/green versus brown), hair
colour (brown/black versus blond/red), skin colour (fair versus
brown), number of naevi ($25 versus ,25), presence of lentigines
(yes versus no) and childhood sunburn (yes versus no) as the outcome
variables.
A Bonferroni-adjusted nominal p-value threshold of 0.00015 was
used to account for multiple testing, based on 341 effective
independent marker loci (N*) among 363 SNPs studied. N* was
calculated by applying the web-based programme SNPSpD [51]
to SNPs on individual chromosomes (http://gump.qimr.edu.au/
general/daleN/SNPSpD/). Fisher’s exact test had been used to
account for differences in allele frequencies between HapMap
CEU data and Spanish population data.
To study combinations of protective and risk genotypes, we used
a2 62 contingency table and a t-student test between SLC45A2
and SILV (rs35414 and rs2069398 respectively), between TYR and
ADAMTS20 (rs17793678 and rs1510521 respectively) and between
previous published results of MC1R (0, 1 or 2 variants) [22] and
SLC45A2 (rs35414).
Haplotype analysis was performed using the SNPstats pro-
gramme available at: http://bioinfo.iconcologia.net/index.php?
module=Snpstats.
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